Clinical Study for AL-CM

Recruiting

• Conditions: Immunoglobulin Light Amyloidosis Cardiomyopathy
• Interventions: Drug: current treatment of AL-CM

• Registration Number: NCT04924998
• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Brief Summary

In this study, patients diagnosed with Al-CM were selected to observe the effect of treatment and conduct long-term follow-up.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-01
• Study First Submitted: 2021-06-07
• Study First Submitted QC: 2021-06-07
• Study First Posted: 2021-06-14
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-29
• Last Update Posted: 2023-01-31
• Primary Completion: 2031-06-01
• Study Completion: 2031-06-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• Patients aged 18-90 years, regardless of gender, diagnosed with Al-CM at the Second Affiliated Hospital of Zhejiang University School of Medicine;
• Patients have the ability to understand the test, can cooperate with investigators.

Exclusion Criteria

• Unable to understand or unwilling to fill in informed consent forms or follow visitors

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
AL-CM	current treatment of AL-CM	-

Primary Outcome Measures

Name	Time	Method
Primary Outcome	10 year	incidences of MACE-4(cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina)

Trial Locations

Locations (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University, China; 🇨🇳 Hangzhou, Zhejiang, China